|
1
|
Sant M, Allemani C, Santaquilani M, Knijn
A, Marchesi F and Capocaccia R: EUROCARE Working Group: EUROCARE-4.
Survival of cancer patients diagnosed in 1995–1999. Results and
commentary. Eur J Cancer. 45:931–991. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sant M, Chirlaque Lopez MD, Agresti R,
Sánchez Perez MJ, Holleczek B, Bielska-Lasota M, Dimitrova N, Innos
K, Katalinic A, Langseth H, et al: Survival of women with cancers
of breast and genital organs in Europe 1999–2007: Results of the
EUROCARE-5 study. Eur J Cancer. 51:2191–2205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ,
Bast R, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, et al:
Rethinking ovarian cancer II: Reducing mortality from high-grade
serous ovarian cancer. Nat Rev Cancer. 15:668–679. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matulonis UA, Sood AK, Fallowfield L,
Howitt BE, Sehouli J and Karlan BY: Ovarian cancer. Nat Rev Dis
Primers. 2:160612016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Friedlander M, Trimble E, Tinker A,
Alberts D, Avall-Lundquist E, Brady M, Harter P, Pignata S,
Pujade-Lauraine E, Sehouli J, et al: Clinical trials in recurrent
ovarian cancer. Int J Gynecol Cancer. 21:771–775. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alvarez RD, Matulonis UA, Herzog TJ,
Coleman RL, Monk BJ and Markman M: Moving beyond the platinum
sensitive/resistant paradigm for patients with recurrent ovarian
cancer. Gynecol Oncol. 141:405–409. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bell D, Berchuck A, Birrer M, Chien J,
Cramer D, Dao F, Dhir R, DiSala P, Gabra H, Glenn P, et al:
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tothill RW, Tinker AV, George J, Brown R,
Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro
B, et al: Novel molecular subtypes of serous and endometrioid
ovarian cancer linked to clinical outcome. Clin Cancer Res.
14:5198–5208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Verhaak RG, Tamayo P, Yang JY, Hubbard D,
Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH,
et al: Prognostically relevant gene signatures of high-grade serous
ovarian carcinoma. J Clin Invest. 123:517–525. 2013.PubMed/NCBI
|
|
10
|
Konecny GE, Wang C, Hamidi H, Winterhoff
B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, et al:
Prognostic and therapeutic relevance of molecular subtypes in
high-grade serous ovarian cancer. J Natl Cancer Inst. 106(pii):
dju2492014.PubMed/NCBI
|
|
11
|
Nelson BH: New insights into tumor
immunity revealed by the unique genetic and genomic aspects of
ovarian cancer. Curr Opin Immunol. 33:93–100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hwang WT, Adams SF, Tahirovic E, Hagemann
IS and Coukos G: Prognostic significance of tumor-infiltrating T
cells in ovarian cancer: A meta-analysis. Gynecol Oncol.
124:192–198. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hao D, Liu J, Chen M, Li J, Wang L, Li X,
Zhao Q and Di LJ: Immunogenomic analyses of advanced serous ovarian
cancer reveal immune score is a prognostic factor and an indicator
of chemosensitivity. Clin Cancer Res. 24:3560–3571. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang W, Kryczek I, Dostál L, Lin H, Tan L,
Zhao L, Lu F, Wei S, Maj T, Peng D, et al: Effector T cells
abrogate Stroma-mediated chemoresistance in ovarian cancer. Cell.
165:1092–1105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu S, Tao Z, Hai B, Liang H, Shi Y, Wang
T, Song W, Chen Y, OuYang J, Chen J, et al: miR-424(322) reverses
chemoresistance via T-cell immune response activation by blocking
the PD-L1 immune checkpoint. Nat Commun. 7:114062016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rabinovich GA, Gabrilovich D and Sotomayor
EM: Immunosuppressive strategies that are mediated by tumor cells.
Annu Rev Immunol. 25:267–296. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Castells M, Thibault B, Delord JP and
Couderc B: Implication of tumor microenvironment in
chemoresistance: Tumor-associated stromal cells protect tumor cells
from cell death. Int J Mol Sci. 13:9545–9571. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Baghdadi M, Wada H, Nakanishi S, Abe H,
Han N, Wira E, Endo D, Watari H, Sakuragi N, Hida Y, et al:
Chemotherapy-induced IL34 enhances immunosuppression by
tumor-associated macrophages and mediates survival of
chemoresistant lung cancer cells. Cancer Res. 76:6030–6042. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takeuchi S, Baghdadi M, Tsuchikawa T, Wada
H, Nakamura T, Abe H, Nakanishi S, Usui Y, Higuchi K, Takahashi M,
et al: Chemotherapy-derived inflammatory responses accelerate the
formation of immunosuppressive myeloid cells in the tissue
microenvironment of human pancreatic cancer. Cancer Res.
75:2629–2640. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mukaida N, Sasaki S and Baba T: Chemokines
in cancer development and progression and their potential as
targeting molecules for cancer treatment. Mediators Inflamm.
2014:1703812014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gnjatic S, Bronte V, Brunet LR, Butler MO,
Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN,
et al: Identifying baseline immune-related biomarkers to predict
clinical outcome of immunotherapy. J Immunother Cancer. 5:442017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang WL, Lu Z and Bast RC Jr: The role of
biomarkers in the management of epithelial ovarian cancer. Expert
Rev Mol Diagn. 17:577–591. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Prat J: FIGO Committee on Gynecologic
Oncology: Abridged republication of FIGO's staging classification
for cancer of the ovary, fallopian tube, and peritoneum. Cancer.
121:3452–3454. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2ΔΔCT method. Methods.
25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shimizu Y, Kamoi S, Amada S, Akiyama F and
Silverberg SG: Toward the development of a universal grading system
for ovarian epithelial carcinoma: Testing of a proposed system in a
series of 461 patients with uniform treatment and follow-up.
Cancer. 82:893–901. 1988. View Article : Google Scholar
|
|
27
|
Kaku T, Ogawa S, Kawano Y, Ohishi Y,
Kobayashi H, Hirakawa T and Nakano H: Histological classification
of ovarian cancer. Med Electron Microsc. 36:9–17. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mitchell AJ: Sensitivity × PPV is a
recognized test called the clinical utility index (CUI+). Eur J
Epidemiol. 26:251–252. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Charo IF and Ransohoff RM: The many roles
of chemokines and chemokine receptors in inflammation. N Engl J
Med. 354:610–621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pitteri SJ, Kelly-Spratt KS, Gurley KE,
Kennedy J, Buson TB, Chin A, Wang H, Zhang Q, Wong CH, Chodosh LA,
et al: Tumor microenvironment-derived proteins dominate the plasma
proteome response during breast cancer induction and progression.
Cancer Res. 71:5090–5100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gevaert O, De Smet F, Van Gorp T, Pochet
N, Engelen K, Amant F, De Moor B, Timmerman D and Vergote I:
Expression profiling to predict the clinical behaviour of ovarian
cancer fails independent evaluation. BMC Cancer. 8:182008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Helleman J, Jansen MP, Span PN, van
Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PE,
van der Burg ME, Stoter G, et al: Molecular profiling of platinum
resistant ovarian cancer. Int J Cancer. 118:1963–1971. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gonzalez Bosquet J, Newtson AM, Chung RK,
Thiel KW, Ginader T, Goodheart MJ, Leslie KK and Smith BJ:
Prediction of chemo-response in serous ovarian cancer. Mol Cancer.
15:662016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chung RK, Newtson AM, Mott SL and Gonzalez
Bosquet J: Clinicopathological predictors of responsiveness in
epithelial ovarian cancer: A preliminary institutional study. Proc
Obstet Gynecol. 5:62015. View Article : Google Scholar
|
|
35
|
Masoumi-Moghaddam S, Amini A, Wei AQ,
Robertson G and Morris DL: Vascular endothelial growth factor
expression correlates with serum CA125 and represents a useful tool
in prediction of refractoriness to platinum-based chemotherapy and
ascites formation in epithelial ovarian cancer. Oncotarget.
6:28491–28501. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Angioli R, Capriglione S, Aloisi A, Guzzo
F, Luvero D, Miranda A, Damiani P, Montera R, Terranova C and
Plotti F: Can HE4 predict platinum response during first-line
chemotherapy in ovarian cancer? Tumor Biol. 35:7009–7015. 2014.
View Article : Google Scholar
|
|
37
|
Chudecka-Głaz A, Cymbaluk-Płoska A,
Wężowska M and Menkiszak J: Could HE4 level measurements during
first-line chemotherapy predict response to treatment among ovarian
cancer patients? PLoS One. 13:e01942702018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pogge von Strandmann E, Reinartz S, Wager
U and Müller R: Tumor-host cell interactions in ovarian cancer:
Pathways to therapy failure. Trends Cancer. 3:137–148. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Senthebane DA, Rowe A, Thomford NE,
Shipanga H, Munro D, Mazeedi MAM, Almazyadi HAM, Kallmeyer K,
Dandara C, Pepper MS, et al: The role of tumor microenvironment in
chemoresistance: To survive, keep your enemies closer. Int J Mol
Sci. 18(pii): E15862017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
de Visser KE and Jonkers J: Towards
understanding the role of cancer-associated inflammation in
chemoresistance. Curr Pharm Des. 15:1844–1853. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Szajnik M, Szczepanski MJ, Czystowska M,
Elishaev E, Mandapathil M, Nowak-Markwitz E, Spaczynski M and
Whiteside TL: TLR4 signaling induced by lipopolysaccharide or
paclitaxel regulates tumor survival and chemoresistance in ovarian
cancer. Oncogene. 28:4353–4363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Q, Li D, Zhang W, Tang B, Li QQ and
Li L: Evaluation of proteomics-identified CCL18 and CXCL1 as
circulating tumor markers for differential diagnosis between
ovarian carcinomas and benign pelvic masses. Int J Biol Markers.
26:262–273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bolitho C, Hahn MA, Baxter RC and Marsh
DJ: The chemokine CXCL1 induces proliferation in epithelial ovarian
cancer cells by transactivation of the epidermal growth factor
receptor. Endocr Relat Cancer. 17:929–940. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Scapini P, Morini M, Tecchio C, Minghelli
S, Di Carlo E, Tanghetti E, Albini A, Lowell C, Berrton G, Noonan
DM and Cassatella MA: CXCL1/macrophage inflammatory
protein-2-induced angiogenesis in vivo is mediated by
neutrophil-derived vascular endothelial growth factor-A. J Immunol.
172:5034–5040. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Acharyya S, Oskarsson T, Vanharanta S,
Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N,
Seshan VE, et al: A CXCL1 paracrine network links cancer
chemoresistance and metastasis. Cell. 150:165–178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Son DS, Kabir SM, Dong Y, Lee E and
Adunyah SE: Characteristics of chemokine signatures elicited by EGF
and TNF in ovarian cancer cells. J Inflamm. 10:252013. View Article : Google Scholar
|
|
47
|
Marsigliante S, Vetrugno C and Muscella A:
CCL20 induces migration and proliferation on breast epithelial
cells. J Cell Physiol. 228:1873–1883. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Beider K, Abraham M, Begin M, Wald H,
Weiss ID, Wald O, Pikarsky E, Abramovitch R, Zeira E, Galun E, et
al: Interaction between CXCR4 and CCL20 pathways regulates tumor
growth. PLoS One. 4:e51252009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Greaves DR, Wang W, Dairaghi DJ, Dieu MC,
Saint-Vis B, Franz-Bacon K, Rossi D, Caux C, McClanahan T, Gordon
S, et al: CCR6, a CC chemokine receptor that interacts with
macrophage inflammatory protein 3α and is highly expressed in human
dendritic cells. J Exp Med. 186:837–844. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cook KW, Letley DP, Ingram RJ, Staples E,
Skjoldmose H, Atherton JC and Robinson K: CCL20/CCR6-mediated
migration of regulatory T cells to the Helicobacter
pylori-infected human gastric mucosa. Gut. 63:1550–1559. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu JY, Li F, Wang LP, Chen XF, Wang D,
Cao L, Ping Y, Zhao S, Li B, Thorne SH, et al: CTL- vs
Treg lymphocyte-attracting chemokines, CCL4 and CCL20,
are strong reciprocal predictive markers for survival of patients
with oesophageal squamous cell carcinoma. Br J Cancer. 113:747–755.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zsiros E, Duttagupta P, Dangaj D, Li H,
Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, et
al: The ovarian cancer chemokine landscape is conducive to homing
of vaccine-primed and CD3/CD28-costimulated T cells prepared for
adoptive therapy. Clin Cancer Res. 21:2840–2850. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tokunaga R, Zhang W, Naseem M, Puccini A,
Berger MD, Soni S, McSkane M, Baba H and Lenz HJ: CXCL9, CXCL10,
CXCL11/CXCR3 axis for immune activation-a target for novel cancer
therapy. Cancer Treat Rev. 63:40–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bronger H, Singer J, Windmüller C, Reuning
U, Zech D, Delbridge C, Dorn J, Kiechle M, Schmalfeldt B, Schmitt M
and Avril S: CXCL9 and CXCL10 predict survival and are regulated by
cyclooxygenase inhibition in advanced serous ovarian cancer. Br J
Cancer. 115:553–563. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mir MA, Maurer MJ, Ziesmer SC, Slager SL,
Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW, et
al: Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are
associated with a poor prognosis in follicular lymphoma. Blood.
125:992–998. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Flores RJ, Kelly AJ, Li Y, Nakka M,
Barkauskas DA, Krailo M, Wang LL, Perlaky L, Lau CC, Hicks MJ, et
al: A novel prognostic model for osteosarcoma using circulating
CXCL10 and FLT3LG. Cancer. 123:144–154. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hong JY, Ryu KJ, Lee JY, Park C, Ko YH,
Kim WS and Kim SJ: Serum level of CXCL10 is associated with
inflammatory prognostic biomarkers in patients with diffuse large
B-cell lymphoma. Hematol Oncol. 35:480–486. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Bai M, Chen X and Ba YI: CXCL10/CXCR3
overexpression as a biomarker of poor prognosis in patients with
stage II colorectal cancer. Mol Clin Oncol. 4:23–30. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Toiyama Y, Fujikawa H, Kawamura M,
Matsushita K, Saigusa S, Tanaka K, Inoue Y, Uchida M, Mohri Y and
Kusunoki M: Evaluation of CXCL10 as a novel serum marker for
predicting liver metastasis and prognosis in colorectal cancer. Int
J Oncol. 40:560–566. 2012.PubMed/NCBI
|
|
60
|
Specht K, Harbeck N, Smida J, Annecke K,
Reich U, Naehrig J, Langer R, Mages J, Busch R, Kruse E, et al:
Expression profiling identifies genes that predict recurrence of
breast cancer after adjuvant CMF-based chemotherapy. Breast Cancer
Res Treat. 118:45–56. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
K Au K, Peterson N, Truesdell P,
Reid-Schachter G, Khalaj K, Ren R, Francis JA, Graham CH, Craig AW
and Koti M: CXCL10 alters the tumour immune microenvironment and
disease progression in a syngeneic murine model of high-grade
serous ovarian cancer. Gynecol Oncol. 145:436–445. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Redjimi N, Raffin C, Raimbaud I, Pignon P,
Matsuzaki J, Odunsi K, Valmori D and Ayyoub M: CXCR3+ T
regulatory cells selectively accumulate in human ovarian carcinomas
to limit type I immunity. Cancer Res. 72:4351–4360. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sato E, Olson SH, Ahn J, Bundy B,
Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone
C, et al: Intraepithelial CD8+ tumor-infiltrating
lymphocytes and a high CD8+/regulatory T cell ratio are
associated with favorable prognosis in ovarian cancer. Proc Natl
Acad Sci USA. 102:18538–18543. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Casrouge A, Decalf J, Ahloulay M, Lababidi
C, Mansour H, Vallet-Pichard A, Mallet V, Mottez E, Mapes J,
Fontanet A, et al: Evidence for an antagonist form of the chemokine
CXCL10 in patients chronically infected with HCV. J Clin Invest.
121:308–317. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Rainczuk A, Rao JR, Gathercole JL,
Fairweather NJ, Chu S, Masadah R, Jobling TW, Deb-Choudhury S, Dyer
J and Stephens AN: Evidence for the antagonistic form of CXC-motif
chemokine CXCL10 in serous epithelial ovarian tumours. Int J
Cancer. 134:530–541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ding Q, Lu P, Xia Y, Ding S, Fan Y, Li X,
Han P, Liu J, Tian D and Liu M: CXCL9: Evidence and contradictions
for its role in tumor progression. Cancer Med. 5:3246–3259. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Chen DS and Mellman I: Oncology meets
immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Peng W, Liu C, Xu C, Lou Y, Chen J, Yang
Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, et al: PD-1 blockade
enhances T-cell migration to tumors by elevating IFN-γ inducible
chemokines. Cancer Res. 72:5209–5218. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Bedognetti D, Spivey TL, Zhao Y, Uccellini
L, Tomei S, Dudley ME, Ascierto ML, De Giorgi V, Liu Q, Delogu LG,
et al: CXCR3/CCR5 pathways in metastatic melanoma patients treated
with adoptive therapy and interleukin-2. Br J Cancer.
109:2412–2423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Harlin H, Meng Y, Peterson AC, Zha Y,
Tretiakova M, Slingluff C, McKee M and Gajewski TF: Chemokine
expression in melanoma metastases associated with CD8+
T-cell recruitment. Cancer Res. 69:3077–3085. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Tarhini AA, Lin Y, Lin HM, Vallabhaneni P,
Sander C, LaFramboise W and Hamieh L: Expression profiles of
immune-related genes are associated with neoadjuvant ipilimumab
clinical benefit. Oncoimmunology. 6:e12312912016. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ayers M, Lunceford J, Nebozhyn M, Murphy
E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran
V, et al: IFN-γ-related mRNA profile predicts clinical response to
PD-1 blockade. J Clin Invest. 127:2930–2940. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Yamazaki N, Kiyohara Y, Uhara H, Iizuka H,
Uehara J, Otsuka F, Fujisawa Y, Takenouchi T, Isei T, Iwatsuki K,
et al: Cytokine biomarkers to predict antitumor responses to
nivolumab suggested in a phase 2 study for advanced melanoma.
Cancer Sci. 108:1022–1031. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Choueiri TK, Fishman MN, Escudier B,
McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL,
McNeel DG, Curti B, et al: Immunomodulatory activity of nivolumab
in metastatic renal cell carcinoma. Clin Cancer Res. 22:5461–5471.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Hamanishi J, Mandai M and Konishi I:
Immune checkpoint inhibition in ovarian cancer. Int Immunol.
28:339–348. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hamanishi J, Mandai M, Ikeda T, Minami M,
Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S,
et al: Safety and antitumor activity of anti-PD-1 antibody,
nivolumab, in patients with platinum-resistant ovarian cancer. J
Clin Oncol. 33:4015–4022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Coosemans A, Decoene J, Baert T, Laenen A,
Kasran A, Verschuere T, Seys S and Vergote I: Immunosuppressive
parameters in serum of ovarian cancer patients change during the
disease course. Oncoimmunology. 5:e11115052016. View Article : Google Scholar : PubMed/NCBI
|
